- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04176198
Um estudo de TP-3654 oral em pacientes com mielofibrose
Um estudo de Fase 1/2, aberto, escalonamento de dose, segurança, farmacocinética e farmacodinâmica do TP-3654 oral em pacientes com mielofibrose primária ou secundária de risco intermediário ou alto
This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Arm 1 will enroll patients who have been previously treated and failed on a JAK inhibitor or ineligible to receive treatment with a JAK inhibitor.
Arm 2 will enroll patients who are on a stable dose of ruxolitinib, but who have either lost response or had a suboptimal or plateau in response.
Arm 3 will enroll patients who have been previously treated with a JAK inhibitor (except momelotinib)
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: Reyna Bishop
- Número de telefone: 617-674-6800
- E-mail: reyna.bishop@us.sumitomo-pharma.com
Estude backup de contato
- Nome: Jordan Simpson
- E-mail: jordan.simpson@us.sumitomo-pharma.com
Locais de estudo
-
-
-
Halle, Alemanha
- Recrutamento
- Universitätsmedizin Halle
-
Contato:
- SMPA Investigative Site
-
Lübeck, Alemanha
- Recrutamento
- Universitätsklinikum Schleswig-Holstein
-
Contato:
- SMPA Investigative Site
-
-
-
-
-
Adelaide, Austrália
- Recrutamento
- Icon Cancer Centre (Ashford Cancer Centre Research)
-
Contato:
- Stanley Cheung, MD
- E-mail: Stanley.Cheung@icon.team
-
-
South Australia
-
Adelaide, South Australia, Austrália
- Recrutamento
- Royal Adelaide Hospital
-
Contato:
- Christine Hoare
- E-mail: christine.hoare@sa.gov.au
-
-
Victoria
-
Box Hill, Victoria, Austrália
- Recrutamento
- Eastern Health Box Hill Hospital
-
Contato:
- SMPA Investigative Site
-
Clayton, Victoria, Austrália
- Recrutamento
- Monash University
-
Contato:
- SMPA Investigative Site
-
Fitzroy, Victoria, Austrália
- Recrutamento
- St Vincent's Hospital Melbourne
-
Contato:
- SMPA Investigative Site
-
Melbourne, Victoria, Austrália
- Recrutamento
- Peter McCallum Center
-
Contato:
- SMPA Investigative Site
-
Richmond, Victoria, Austrália
- Recrutamento
- Epworth Healthcare
-
Contato:
- SMPA Investigative Site
-
-
-
-
-
Antwerp, Bélgica, 2020
- Recrutamento
- ZNA Cadix
-
Contato:
- SMPA Investigative Site
-
Antwerp, Bélgica, 2030
- Recrutamento
- ZNA Middelheim
-
Contato:
- SMPA Investigative Site
-
Ghent, Bélgica, 9000
- Recrutamento
- Universitair Ziekenhuis Gent
-
Contato:
- SMPA Investigative Site
-
Liège, Bélgica, 4000
- Recrutamento
- CHU de Liege
-
Contato:
- SMPA Investigative Site
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Bélgica, 3000
- Recrutamento
- University Hospitals Leuven
-
Contato:
- SMPA Investigative Site
-
-
-
-
Alberta
-
Calgary, Alberta, Canadá, T2N 1N4
- Recrutamento
- University of Calgary
-
Contato:
- Sonia Cerquozzi
- E-mail: sonia.cerquozzi@albertahealthservices.ca
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V6T 1Z3
- Recrutamento
- University of British Columbia
-
Contato:
- SMPA Investigative Site
-
Vancouver, British Columbia, Canadá, V6T 1Z3
- Recrutamento
- St. Paul's Hospital Hematology/Oncology Research
-
Contato:
- Kelsi Sorensen
- Número de telefone: 604-682-2344
- E-mail: ksorensen1@providencehealth.bc
-
-
Ontario
-
Hamilton, Ontario, Canadá, L8V 5C2
- Recrutamento
- Juravinski Cancer Center
-
Contato:
- SMPA Investigative Site
-
Toronto, Ontario, Canadá, M5G 2M9
- Recrutamento
- Princess Margaret Cancer Center
-
Contato:
- Vikas Gupta
- E-mail: vikas.gupta@uhn.ca
-
-
Quebec
-
Montreal, Quebec, Canadá, H3T 1E2
- Recrutamento
- Jewish General Hospital
-
Contato:
- SMPA Investigative Site
-
-
-
-
-
Barcelona, Espanha
- Recrutamento
- Hospital Universitario y Politecnico La Fe
-
Contato:
- SMPA Investigative Site
-
Barcelona, Espanha
- Recrutamento
- Institut Catala d'Oncologia
-
Contato:
- SMPA Investigative Site
-
Salamanca, Espanha
- Recrutamento
- Hospital Universitario de Salamanca
-
Contato:
- SMPA Investigative Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35294
- Recrutamento
- University of Alabama
-
Contato:
- Tiffany Hill
- Número de telefone: 205-934-9591
-
-
Arizona
-
Tucson, Arizona, Estados Unidos, 85724
- Recrutamento
- The University of Arizona Cancer Center
-
Contato:
- Audrey Johnson
- Número de telefone: 520-694-9084
- E-mail: audieejayy@arizona.edu
-
-
California
-
Duarte, California, Estados Unidos, 91010
- Recrutamento
- City of Hope
-
Contato:
- Michelle Velasquez
- Número de telefone: 626-218-3524
- E-mail: mvelaszuez@coh.org
-
Los Angeles, California, Estados Unidos, 90033
- Recrutamento
- University of Southern California
-
Contato:
- Shirley Sian
- Número de telefone: 323-865-0456
- E-mail: sian_s@med.usc.edu
-
Newport Beach, California, Estados Unidos, 92663
- Recrutamento
- Hoag Family Cancer Institute
-
Contato:
- Patrice Jones
- Número de telefone: 949-764-5501
- E-mail: patrice.jones@hoag.org
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80218
- Recrutamento
- Blood Cancer Center
-
Contato:
- Brooke Rhodes
- E-mail: Brookerhodes@sarahcannon.com
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06510
- Recrutamento
- Yale School of Medicine
-
Contato:
- Farah Fasihuddin
- Número de telefone: 203-494-4610
- E-mail: farah.fasihuddin@yale.edu
-
-
Florida
-
Gainesville, Florida, Estados Unidos, 32608
- Concluído
- University of Florida Health Shands Cancer Hospital
-
Miami, Florida, Estados Unidos, 33136
- Recrutamento
- University of Miami
-
Contato:
- Alessia Zoso
- Número de telefone: 305-243-0327
- E-mail: azoso@miami.edu
-
Miami, Florida, Estados Unidos, 33176
- Recrutamento
- Baptist Health - Miami Cancer Institute
-
Contato:
- Firas El Chaer, MD
- Número de telefone: 786-596-2000
- E-mail: firas.elchaer@baptisthealth.net
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Recrutamento
- Emory University
-
Contato:
- Suzanne Scott
- Número de telefone: 404-778-4334
- E-mail: suzanne.e.scott@emory.edu
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60637
- Recrutamento
- University of Chicago
-
Contato:
- Howie Weiner
- E-mail: HWeiner@bsd.uchicago.edu
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21201
- Recrutamento
- University of Maryland
-
Contato:
- Maria Baer, MD
- Número de telefone: 410-328-8708
- E-mail: mbaer@umm.edu
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Recrutamento
- Massachusetts General Hospital
-
Contato:
- Gabriela Hobbs, MD
- E-mail: ghobbs@mgb.org
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- Recrutamento
- University of Michigan
-
Contato:
- Kelsey Bolin
- Número de telefone: 734-936-2193
- E-mail: kntillma@med.umich.edu
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455
- Recrutamento
- University of Minnesota
-
Contato:
- Naveen Premnath, MD
- E-mail: premn007@umn.edu
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Recrutamento
- Washington University of Medicine
-
Contato:
- Nicole Gaudin
- Número de telefone: 314-747-7960
- E-mail: nrgaudin@wustl.edu
-
-
New Jersey
-
Hackensack, New Jersey, Estados Unidos, 07601
- Recrutamento
- John Theurer Cancer Center at Hackensack University Medical Center
-
Contato:
- Parita Patel
- Número de telefone: 551-996-5900
- E-mail: parita.patel@hmhn.org
-
-
New York
-
Buffalo, New York, Estados Unidos, 14263
- Concluído
- Roswell Park Comprehensive Cancer Center
-
New York, New York, Estados Unidos, 10065
- Recrutamento
- Memorial Sloan Kettering Cancer Center
-
Contato:
- Tamanna Haque, MD
- E-mail: haquet1@mskcc.org
-
New York, New York, Estados Unidos, 10029
- Recrutamento
- Icahn School of Medicine at Mount Sinai
-
Contato:
- Gabriela Bello
- E-mail: gabriela.bello@mssm.edu
-
New York, New York, Estados Unidos, 10065
- Recrutamento
- Weill Cornell Medical Center
-
Contato:
- Penina Steward
- Número de telefone: 212-746-1858
- E-mail: pes4006@med.cornell.edu
-
The Bronx, New York, Estados Unidos, 10461
- Recrutamento
- Montefiore Cancer Center
-
Contato:
- Olivia Orellano
- E-mail: oorellano@montefiore.org
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27710
- Recrutamento
- Duke Cancer Institute
-
Contato:
- Ben Dosan
- E-mail: benjamin.dosan@duke.edu
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43210
- Recrutamento
- Ohio State University
-
Contato:
- Molly Brandenburg
- Número de telefone: 614-366-7951
- E-mail: Molly.Brandenburg@osumc.edu
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29425
- Recrutamento
- Medical University of South Carolina
-
Contato:
- Jared Hortman
- E-mail: hortman@musc.edu
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37232
- Recrutamento
- Vanderbilt University
-
Contato:
- SMPA Investigative Site
-
Nashville, Tennessee, Estados Unidos, 37203
- Recrutamento
- Tri-Star Centennial Medical Center
-
Contato:
- Brooke Rhodes
- E-mail: brooke.rhodes@sarahcannon.com
-
-
Texas
-
Houston, Texas, Estados Unidos, 77054
- Recrutamento
- MD Anderson Cancer Center
-
Contato:
- Kurt Schroeder
- Número de telefone: 713-745-2232
- E-mail: kdschroe@mdanderson.org
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84112
- Recrutamento
- Huntsman Cancer Institute
-
Contato:
- Nicole Fisher
- Número de telefone: 801-587-7000
- E-mail: nicole.fisher@hci.utah.edu
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22903
- Recrutamento
- University of Virginia Cancer Center
-
Contato:
- Avani Hopkins
- Número de telefone: 434-243-8108
- E-mail: AJH7JQE@uvahealth.org
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98109
- Recrutamento
- University of Washington - Fred Hutchinson Cancer Center
-
Contato:
- Anna Halpern
- E-mail: halpern2@uw.edu
-
-
-
-
-
Amiens, França, 80054
- Recrutamento
- Centre Hospitalier Universitaire D'Amiens
-
Contato:
- SMPA Investigative Site
-
Angers, França, 9000
- Recrutamento
- CHU Angers
-
Contato:
- SMPA Investigative Site
-
Lyon, França, 69495
- Recrutamento
- Centre Hospitalier Lyon Sud
-
Contato:
- SMPA Investigative Site
-
Nice, França, 06200
- Recrutamento
- Hospitalier Universitaire (CHU) de Nice - Hopital de l'Archet
-
Contato:
- SMPA Investigative Site
-
Nîmes, França, 30029
- Recrutamento
- Institut de cancerologie du Gard
-
Contato:
- SMPA Investigative Site
-
Nîmes, França
- Recrutamento
- Institut de cancerologie du Gard
-
Contato:
- SMPA Investigative Site
-
Paris, França, 75010
- Recrutamento
- Hospital Saint Louis
-
Contato:
- SMPA Investigative Site
-
Poitiers, França, 86021
- Recrutamento
- University Hospital of Poitiers
-
Contato:
- SMPA Investigative Site
-
Villejuif, França, 94805
- Recrutamento
- Institut Gustave Roussy
-
Contato:
- SMPA Investigative Site
-
-
-
-
-
Alessandria, Itália, 15121
- Recrutamento
- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo
-
Contato:
- SMPA Investigative Site
-
Aviano, Itália, 33081
- Recrutamento
- Istituto Nazionale Tumori, IRCCS Centro di Riferimento Oncologico di Aviano
-
Bologna, Itália, 40138
- Recrutamento
- IRCCS Azienda Ospedaliero -Universitaria Di Bologna - Dipartimento Malattie Oncologiche ed Ematologiche - UO Ematologia
-
Contato:
- SMPA Investigative Site
-
Brescia, Itália
- Recrutamento
- ASST - Spedali Civili di Brescia
-
Contato:
- SMPA Investigative Site
-
Meldola, Itália, 47014
- Recrutamento
- IRCCS istituto Romagnolo per lo studio dei tumori "Dino Amadori"
-
Contato:
- SMPA Investigative Site
-
Milan, Itália, 20122
- Recrutamento
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
Contato:
- SMPA Investigative Site
-
Torino, Itália, 10126
- Recrutamento
- Azienda Ospedaliera Universitaria Citta' Della Salute E della Scienza di Torino
-
Contato:
- SMPA Investigative Site
-
-
-
-
-
Aichi, Japão
- Recrutamento
- Aichi Medical University Hospital
-
Contato:
- Akiyoshi Takami
- Número de telefone: 0561-62-3311
- E-mail: takami.akiyoshi.490@mail.aichi-med-u.ac.jp
-
Aomori, Japão
- Recrutamento
- Aomori Prefectural Central Hospital
-
Contato:
- Tomoaki Akagi, MD
- Número de telefone: 017-726-8111
- E-mail: tomakagi@med.pref.aomori.jp
-
Chiba, Japão
- Recrutamento
- National Cancer Center Hospital East
-
Contato:
- Junichiro Yuda, MD
- Número de telefone: 04-7133-1111
- E-mail: jyuda@east.ncc.go.jp
-
Fukuoka, Japão
- Recrutamento
- Kyushu University Hospital
-
Contato:
- Takuji Yamauchi, MD
- Número de telefone: 092-641-1151
- E-mail: yamauchi.takuji.355@m.kyushu-u.ac.jp
-
Hokkaido, Japão
- Recrutamento
- Hokkaido University Hospital
-
Contato:
- Takanori Teshima, MD
- Número de telefone: 011-716-1161
- E-mail: teshima@med.hokudai.ac.jp
-
Kamakura, Japão, 247-8533
- Recrutamento
- Shonan Kamakura General Hospital
-
Contato:
- Tomiteru Togano, MD
- Número de telefone: 0467-46-1717
- E-mail: t_togano@shonankamakura.or.jp
-
Miyazaki, Japão
- Recrutamento
- University of Miyazaki Hospital
-
Contato:
- Kazuya Shimoda, MD
- Número de telefone: 0985-85-1510
- E-mail: kshimoda@med.miyazaki-u.ac.jp
-
Okayama, Japão
- Recrutamento
- Okayama University Hospital
-
Contato:
- Noboru Asada, MD
- Número de telefone: 086-223-7151
- E-mail: nasada@okayama-u.ac.jp
-
Osaka, Japão
- Recrutamento
- The University of Osaka Hospital
-
Contato:
- Michiko Ichii, MD
- Número de telefone: 06-6879-5111
-
Saitama, Japão
- Concluído
- Saitama Medical Center
-
Sendai, Japão
- Recrutamento
- Tohoku University Hospital
-
Contato:
- Noriko Fukuhara, MD
- Número de telefone: 022-717-7000
-
Shizuoka, Japão
- Concluído
- Shizuoka Cancer Center
-
Tokyo, Japão, 160-0023
- Recrutamento
- Tokyo Medical University Hospital
-
Contato:
- Daigo Akahane, MD
- Número de telefone: 03-3342-6111
- E-mail: dakahane@tokyo-med.ac.jp
-
Tokyo, Japão
- Recrutamento
- Juntendo University Hospital
-
Contato:
- Shuichi Shirane, MD
- Número de telefone: 03-3813-3111
- E-mail: sshirane@juntendo.ac.jp
-
Tokyo, Japão, 179-0072
- Recrutamento
- Nerima Hikarigaoka Hospital
-
Contato:
- Akihiko Gotoh, MD
- Número de telefone: 03-3979-3611
- E-mail: akgotou@juntendo.ac.jp
-
Tsu, Japão
- Recrutamento
- Mie University Hospital
-
Contato:
- Yuka Sugimoto, MD
- Número de telefone: 059-232-1111
- E-mail: yuka2@clin.medic.mie-u.ac.jp
-
-
-
-
-
Lincoln, Reino Unido
- Recrutamento
- Lincoln County Hospital
-
Contato:
- SMPA Investigative Site
-
Lincoln, Reino Unido
- Recrutamento
- United Lincolnshire Hospitals NHS Trust - Pilgrim Hospital
-
Contato:
- SMPA Investigative Site
-
London, Reino Unido
- Recrutamento
- University College London Hospital's NHS foundation Trust
-
Contato:
- SMPA Investigative Site
-
Oxford, Reino Unido
- Recrutamento
- Oxford University Hospitals NHS Foundation
-
Contato:
- SMPA Investigative Site
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Patients must meet all of the following inclusion criteria to be eligible:
Nuvisertib (TP-3654) Monotherapy Arm:
- Confirmed pathological diagnosis of primary myelofibrosis (PMF) or post-PV-MF/post-ET- MF and intermediate or high-risk primary or secondary MF
- Previously treated with JAK inhibitor(s) and is intolerant, resistant, refractory or has lost response to the JAK inhibitor(s) or is ineligible to be treated with JAK inhibitor
- Fulfill the following clinical laboratory parameters:
- Platelet count ≥ 25 x 10^9 /L, without assistance of growth factors or platelet transfusions
- ANC ≥ 1 x 10^9/L without assistance of granulocyte growth factors
- Peripheral blood blast count < 5%
- ECOG performance status ≤ 1
- Life expectancy ≥ 6 months
- Adequate renal function
- Adequate hepatic function
- Adequate coagulation function
- Splenomegaly (spleen volume of ≥ 450 cm3 by MRI or CT scan) within 2 weeks prior to Cycle 1 Day 1.
- Dose escalation: At least 2 symptoms measurable (score ≥ 1) using the MF-SAF
- Dose expansion: At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF
Nuvisertib (TP-3654) + Ruxolitinib Arm:
- Confirmed pathological diagnosis of PMF or post-PV-MF/post ET- MF and intermediate or high-risk primary or secondary MF
- On ruxolitinib treatment for ≥ 6 months, and on a stable dose of ruxolitinib (5 to 25 mg BID) for ≥ 8 weeks prior to the first dose of nuvisertib, but has either lost response or had a suboptimal or plateau in response
- Fulfills the following clinical laboratory parameters:
- Platelet count ≥ 50 × 10^9/L (without assistance of growth factors or platelet transfusions)
- ANC ≥ 1 × 109/L without assistance of granulocyte growth factors
- Peripheral blood blast count < 5% at screening
- Adequate renal function
- Adequate hepatic function
- Adequate coagulation function
- Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1
- At least 2 symptoms measurable with each score ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
- ECOG performance status ≤ 1
- Life expectancy ≥ 6 months
Nuvisertib (TP-3654) + Momelotinib Arm
- Confirmed pathological diagnosis of PMF or post-PV-MF/post ET-MF and intermediate or high-risk primary or secondary MF
- Previously treated with an approved JAK inhibitor (except momelotinib) for PMF or Post-PV/ET MF for ≥ 12 weeks, or ≥ 4 weeks if JAK inhibitor therapy was complicated by a transfusion requirement of ≥ 4 units of red blood cells in 8 weeks, or Grade 3/4 AEs of thrombocytopenia, anemia, or hematoma
- Fulfills the following clinical laboratory parameters:
- Anemic, defined as Hb <10 g/dL or requiring RBC transfusion at baseline
- Platelet count ≥ 50 × 109/L (without assistance of growth factors or platelet transfusions)
- ANC ≥ 1 × 109/L without assistance of granulocyte growth factors
- Peripheral blood blast count < 5% at screening
- Adequate renal function
- Adequate hepatic function
- Adequate coagulation function
- Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1
- At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
- ECOG performance status ≤ 1
- Life expectancy ≥ 6 months
Patients meeting any one of these exclusion criteria will be prohibited from participating in this study:
Nuvisertib (TP-3654) Monotherapy Arm:
- Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
- Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or not recovered adequately from from surgery prior to first dose.
- Splenic irradiation within 6 months prior to Screening or prior splenectomy.
- Prior allogeneic stem cell transplant within the last 6 months.
- Eligible for allogeneic bone marrow or stem cell transplantation.
- Unresolved Grade ≥ 2 non-hematological toxicity related to prior treatment
- History of symptomatic congestive heart failure, or myocardial infarction, or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; left ventricular ejection fraction (LVEF) < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1.
- Corrected QT interval > 480msec.
- Prior or concurrent malignancy that could interfere with the investigational regime.
- Known history of chronic liver disease, e.g. portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc.
- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic antimicrobial within 1 week prior to Cycle 1 Day 1.
- Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
- Exhibited allergic reactions or sensitivity to nuvisertib, or similar compound.
- Medical condition or GI tract surgery that could impair absorption or result in short bowel syndrome with diarrhea.
- Systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to the first dose of study treatment (note: topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
- Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding.
- Pregnant or breastfeeding
- Currently receiving any other investigational agent.
Nuvisertib (TP-3654) + Ruxolitinib Arm:
- Received previous systemic antineoplastic therapy (other than ruxolitinib) or any other experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Note: Prior treatment with nuvisertib is not allowed. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
- Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited)
- Known allergic reactions or sensitivity to nuvisertib, or similar compound.
- Splenic irradiation within 6 months prior to Screening or prior splenectomy
- Prior allogeneic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
- Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible.)
- Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately prior to first dose.
- Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
- Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
- Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed).
- Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
- History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF <45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
- Corrected QTcF of > 480 msec
- Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention
- History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
- Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding
- Pregnant or breastfeeding
Nuvisertib (TP-3654) + Momelotinib Arm:
- Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Notes: Prior treatment with momelotinib or nuvisertib is not allowed; in patients with ongoing JAK inhibitor therapy, ie, ruxolitinib, at screening, JAK inhibitor therapy must be tapered over a period of at least 1 week. Patients on a low dose of ruxolitinib (eg, 5 mg QD) may have a reduced taper period or no taper; hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
- Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
- Known allergic reactions or sensitivity to nuvisertib, momelotinib, or any structurally similar drug, or to any component of the formulations of either study intervention
- Splenic irradiation within 6 months prior to screening or prior splenectomy
- Prior allogenic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
- Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible).
- Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately from surgery prior to first dose.
- Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
- Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
- Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed)
- Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
- Presence of Grade ≥ 2 peripheral neuropathy
- History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
- Corrected QTcF of > 480 msec
- Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention
- History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
- Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding
- Pregnant or breastfeeding
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Braço 1: nuvisertib (TP-3654)
|
Oral PIM Inhibitor
Outros nomes:
|
|
Experimental: Braço 2: nuvisertibe (TP-3654) adicionado ao ruxolitinibe
|
Oral PIM Inhibitor
Outros nomes:
Oral JAK inhibitor
Outros nomes:
|
|
Experimental: Braço 3: nuvisertibe (TP-3654) em combinação com momelotinibe
|
Oral PIM Inhibitor
Outros nomes:
Oral JAK inhibitor
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Determine the incidence of dose-limiting toxicities (DLTs)
Prazo: 28 days
|
Number of participants with DLTs |
28 days
|
|
Determine the incidence of treatment emergent adverse events
Prazo: From start of treatment to end of study
|
Number of participants with Treatment Emergent Adverse Events and Serious Adverse Events |
From start of treatment to end of study
|
|
Assess patients for any evidence of preliminary activity by determining the number of patients with ≥ 35% spleen volume reduction (SVR35)
Prazo: From start of treatment to end of study
|
Number of participants with ≥ 35% spleen volume reduction (SVR35) |
From start of treatment to end of study
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of participants achieving objective response by IWG-MRT response criteria
Prazo: From start of treatment to end of study
|
Number of participants achieving complete remission, partial remission, clinical improvement, progressive disease and stable disease. |
From start of treatment to end of study
|
|
Number of participants who have ≥ 25% spleen volume reduction
Prazo: Every 12 weeks from cycle 1 day 1 through cycle 19 day 1, and then every 24 weeks therafter during treatment.
|
Number of participants who have ≥ 25% spleen volume reduction compared to baseline |
Every 12 weeks from cycle 1 day 1 through cycle 19 day 1, and then every 24 weeks therafter during treatment.
|
|
Number of participants with ≥ 50% improvement in total symptom score (TSS50) at week 24
Prazo: 24 weeks
|
Number of participants who have ≥ 50% total symptom score reduction by MFSAF compared to baseline after 24 weeks of treatment. |
24 weeks
|
|
Determine the change in Patient Global Impression of Change (PGIC) at week 24 through end of study.
Prazo: After 24 weeks of treatment to end of study
|
Change in PGIC score |
After 24 weeks of treatment to end of study
|
|
Determine the incidence of QT interval changes
Prazo: 25 hours
|
Changes in QT interval and heart rhythm |
25 hours
|
|
Establish the half-life (t½) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Prazo: 24 hours
|
The estimate of time for the nuvisertib concentration or amount to be reduced by half |
24 hours
|
|
Establish the Area under the plasma concentration versus time curve (AUC) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Prazo: 24 hours
|
The amount of drug exposure over 24 hours period after administration |
24 hours
|
|
Establish the Peak Plasma Concentration (Cmax) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Prazo: 24 hours
|
The maximum nuvisertib concentration after administration |
24 hours
|
|
Establish the Time of Maximum concentration observed (tmax) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Prazo: 24 hours
|
The time to reach maximum nuvisertib concentration |
24 hours
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Número de pacientes com redução da fibrose da medula óssea
Prazo: A cada 24 semanas até o final do estudo
|
A cada 24 semanas até o final do estudo
|
|
|
Braços combinados de Nuvisertib: Avaliar o aumento da hemoglobina ≥1,5 ou ≥ 2 g/dL em relação ao valor basal
Prazo: Do início do tratamento ao final do estudo
|
Do início do tratamento ao final do estudo
|
|
|
Braços combinados de Nuvisertib: Avaliar o estado de independência da transfusão de glóbulos vermelhos ou qualquer alteração de requisitos
Prazo: Do início do tratamento ao final do estudo
|
Do início do tratamento ao final do estudo
|
|
|
Monoterapia com NuVisertib: Alterações na contagem de plaquetas ao longo do tempo em pacientes com contagem inicial de plaquetas <100 x 10^9/L
Prazo: Desde o início do tratamento até o fim do estudo
|
Desde o início do tratamento até o fim do estudo
|
|
|
Study potential pharmacodynamic (PD) markers of nuvisertib
Prazo: 12 months
|
Evaluate exploratory biomarkers, including change in protein phosphorylation and inflammatory cytokines, in peripheral blood samples and bone marrow biopsy samples. |
12 months
|
|
Establish overall survival
Prazo: From start of treatment to end of study
|
The time interval from treatment start date to date of death from any cause |
From start of treatment to end of study
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- BBI-TP-3654-102
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .